Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
ST

NASDAQ · STRO

Sutro Biopharma, Inc.

Healthcare · Biotechnology

$14.45

Down-$0.68 (-4.49%)

Updated Oct 7, 2026, 7:59 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
83.52M
P/E ratio
-0.38
Dividend yield
0.00%
52-week range
$14.27 – $43.85
Volume
162.79K
Avg. volume
105.45K

Price performance · STRO

STRO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

STRO closed at $14.45 after 21 trading sessions, down 24.35% for the selected period.

Last close
$14.45
Period change
-24.35%
Period low
$14.45
Period high
$19.10
Daily close
View OHLC price history
STRO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$15.14$15.47$14.37$14.45162.79K
Oct 5, 2026$15.46$15.46$14.27$15.13160.4K
Oct 2, 2026$16.15$16.15$14.59$15.35372.14K
Oct 1, 2026$16.07$16.32$15.6247$15.97196.93K
Sep 30, 2026$16.22$16.66$15.85$16.11133.97K
Sep 29, 2026$16.05$16.27$15.735$16.10202.4K
Sep 28, 2026$15.89$16.24$15.20$16.03165.7K
Sep 25, 2026$15.61$16.19$14.95$15.98292.05K
Sep 24, 2026$15.68$16.00$15.15$15.71252.9K
Sep 23, 2026$16.09$16.17$15.56$15.73294.02K
Sep 22, 2026$16.43$16.55$16.00$16.13246.24K
Sep 21, 2026$14.99$16.52$14.99$16.35320.34K
Sep 18, 2026$15.58$15.58$14.805$15.34651.38K
Sep 17, 2026$15.94$16.13$15.25$15.48348.38K
Sep 16, 2026$16.66$16.80$15.17$15.60273.3K
Sep 15, 2026$16.82$16.82$15.43$16.561.29M
Sep 14, 2026$17.09$17.41$16.53$16.91251.66K
Sep 11, 2026$18.07$18.27$16.48$16.86942.34K
Sep 10, 2026$18.01$18.21$17.58$17.83169.2K
Sep 9, 2026$19.01$19.464$18.24$18.355145.61K
Sep 8, 2026$19.61$19.755$19.0401$19.10153.54K

Latest STRO news

The latest Smart Investors Daily articles mentioning STRO.

Stock researchCompany · Overview

STRO research

Overview

Company profile and research snapshot.

Company profile

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.86
Implied upside
—
Analysts
—
STRO recent ratings
DateFirmRatingTarget
Aug 13, 2026CitizensMarket Outperform—
Aug 13, 2026WedbushOutperform—
May 28, 2026BarclaysOverweight—
May 15, 2026WedbushOutperform—
May 15, 2026Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026. Mr. Donigian brings more than 20 years of biotechnology industry experience, with a background in business development, corporate strategy

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By